Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma

Authors

Timothy P DiPeri
Mehmet Demirhan
Daniel D Karp
Siqing Fu
David S Hong
Vivek Subbiah
Joann Lim
Leomar Y Ballester
Jean H Tayar
Maria E Suarez-Almazor
Milind Javle
Funda Meric-Bernstam

Publication Date

2-1-2022

Journal

Journal of Immunotherapy and Precision Oncology

DOI

10.36401/JIPO-21-18

PMID

35663835

PMCID

PMC9138421

PubMedCentral® Posted Date

2-4-2022

PubMedCentral® Full Text Version

Post-print

Abstract

Intrahepatic cholangiocarcinoma is a rare malignancy, which is rich in actionable alterations. Genomic aberrations in the mitogen-activated protein kinase (MAPK) pathway are common, and

Keywords

cholangiocarcinoma, precision oncology, targeted therapy, myositis

Published Open-Access

yes

Recommended Citation

DiPeri, Timothy P; Demirhan, Mehmet; Karp, Daniel D; et al., "Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma" (2022). Faculty, Staff and Student Publications. 2552.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/2552